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ABSTRACT
A principal component analysis of the TCGA data for 15 cancer localizations unveils the following
qualitative facts about tumors: 1) The state of a tissue in gene expression space may be described by
a few variables. In particular, there is a single variable describing the progression from a normal
tissue to a tumor. 2) Each cancer localization is characterized by a gene expression profile, in which
genes  have  specific  weights  in  the  definition  of  the  cancer  state.  There  are  no less  than  2500
differentially-expressed  genes,  which  lead  to  power-like  tails  in  the  expression  distribution
functions. 3) Tumors in different localizations share hundreds or even thousands of differentially
expressed genes. There are 6 genes common to the 15 studied tumor localizations. 4) The tumor
region is a kind of attractor. Tumors in advanced stages converge to this region independently of
patient age or genetic variability. 5) There is a landscape of cancer in gene expression space with an
approximate border separating normal tissues from tumors.
INTRODUCTION
Cancer  is  a  very  complex  phenomenon  [1].  From  one  side,  the  number  of  internal  variables
participating in relevant processes in a tissue is huge. The number of human genes, for example, is
around 60000. Trying to infer the behavior of such a system from observations in a few hundred
samples is very challenging. The general laws and state variables are not completely known or
understood. From the other side, as in any aspect of life, ties with the environment are very strong.
Enormous coordinated efforts aimed at understanding basic aspects of cancer have led to many
important results. A lot of information about genes,  cells and tissues have been compiled and put
into public databases [2-4].  The analysis of such information allowed the identification of mutation
signatures, immune characteristics, etc [5-12]. 
From the theoretical point of view, current views to cancer include cell-intrinsic (i.e. genetic &
epigenetic) and cell-extrinsic phenomena (i.e. micro-environment), as well as population genetics
approaches with random drift and directional selection shaping, what has been coined as somatic
evolution  [13,14].  There  is  even  a  plausible  hypothesis  that  cancer  is  an  atavism,  that  is  a
cooperative state of multi-cellular organisms, prior to modern metazoans [15-19].
In spite of all this progress, a simple enough picture, quantifying the evolution of a normal tissue
towards cancer is still lacking. 
In this paper, we present a contribution to the qualitative perspective by stressing a few qualitative
facts  on cancer  which come from the analysis  of gene expression data.  The title  of  the paper,
“cancer gene expression landscape”, indicates the aim at placing all tumors in a single plot and
delineating the border between normal tissues and tumors. 
The data, provided by The Cancer Genome Atlas (TCGA) project [4], is processed by standard
Principal Component Analysis (PCA, [20-22]). In the paper, we avoid using models or elaborated
theoretical constructions that could hide basic facts. Instead of this, we focus on general results
following straightforwardly from the expression data. 
QUALITATIVE RESULTS
We take tissue expression data for 15 cancer localizations from the TCGA project. This is a well
curated  database.  Gene  expressions  are  measured  by  sequencing  the  mRNA produced  in  the
transcription process (RNA-seq, [23]). The data is in the number of fragments per kilo-base of gene
length per mega-base of reads format (FPKM, [24]). We pick up  localizations where there are at
least 10 normal samples, and the number of tumor samples is greater than 160. The studied cases
are shown in Table I.
(Insert Table I)
In  the  Methods  section,  the  PCA used  methodology  is  briefly  explained.  We  take  the  mean
geometric average over normal samples in order to define the reference expression for each gene,
and normalize accordingly to obtain the differential expressions, ē = e/eref. Finally, we take the base
2 logarithm, ê = Log2 (ē), to define the fold variation. Besides reducing the variance, the logarithm
allows treating over- and sub-expression in a symmetrical way. The covariance matrix is defined in
terms of ê. We forced the reference for the PC analysis to be at the center of the cloud of normal
samples. This is what actually happens in a population, where most individuals are healthy and
cancer situations are rare. The eigenvectors of the covariance matrix define the PC axes: PC1, PC2,
etc, and projection over them define the new state variables. By definition, PC1 captures the highest
fraction of the total variance in the sample set.
Statement  1.  The  state  of  a  tissue  in  gene  expression  space  may  be  described  by  a  few
variables. In particular, there is a single variable describing the progression from a normal
tissue to a tumor.
Fig. 1 shows the PCA results for three of the studied tissues: Kidney renal papillary cell carcinoma
(KIRP), Lung squamous cell carcinoma (LUSC) and Liver hepatocellular carcinoma (LIHC). In the
left panel, the distribution of normal and tumor samples in the (PC1, PC2) plane suggests that there
are  well  defined  normal  and  tumor  regions,  and  that  the  first  PC1  variable  may  discriminate
between a normal sample and a tumor. PC1 can thus be labeled as the cancer axis.  
(Insert Fig. 1)
The projection along PC1 may be used to quantify the progression from a normal tissue to a tumor.
Comparison with other qualifications like the tumor stage is interesting. We shall come back to this
point below.
The right panel, on the other hand, evaluates the fraction of total variance captured by the first n PC
variables.  In LUSC, for example,  the first three components account for 74% of the variance.
Notice that with a few such variables we may describe to a considerable extent the complexity of
LUSC.
This reduced number of variables, well below the number of constituent genes, may be taken as the
effective number of degrees of freedom of the complex system represented by a tissue. 
The fraction of variance depends on the sample set, and may vary if we enlarge or reduce the set.
Thus, we should take the results as approximate, semi quantitative ones, that shall improve as the
sample size is enlarged.
However, in spite of the statistical origin of the new variables we may use them to describe the
actual state of a given sample. Each unitary vector along any of the PC axes defines an expression
profile, with a meaning. The fact that with 6 - 10 such variables we may account for 80 % or more
of the data dispersion means that the effective dimensionality of the state space is much less than it
seems.  Genes  do not  take  arbitrary  expressions,  but  act  in  a  concerted  way.  Groups of  genes,
metagenes or sub-networks express themselves as profiles.
Statement 2. Each cancer localization is characterized by a gene expression profile, in which
genes have specific weights in the definition of the cancer state. 
Let us call v1 the eigenvector along PC1 (boldface denotes vectors). We showed above that the PC1
axis accounts for the largest fraction of variance and that projection along it may be taken as an
indicator of the malignant state. For a given  sample with fold expression vector ê , the projection x1
over the PC1 axis is precisely defined as:   
x1  = ê . v1 = Σ êi v1i.
The v1 vector  may be thought to provide a metagene [25] or gene expression profile of cancer in
the tissue, i.e. the set of over- or under-expressed genes (and their relative importance) that define
the cancer state.  V1i is the weight of gene i in the definition of the cancer state. A positive sign
means that the gene is over-expressed in the tumor. 
Fig.  2  left  panel  shows  the  30  genes  with  the  largest  contributions  to  v1 in  the  same tumors
represented in Fig. 1. Note the signs, positive and negative indicating over- and under-expression
respectively. The components of the v1 vector define the weights of these genes in the definition of
the cancer state. In principle, because of their large weights, these 30 genes could be used as cancer
biomarkers, however their specific roles in each tissue deserve further study. In LUSC, for example,
the  gene  with  the  largest  weight  is  SFTPC,  a  silenced  gene  with  an  important  role  in  lung
homeostasis  [26,27].  The  analogous  genes  in  KIRP and  LIHC are  Uromodulin  (UMOD)  and
Cytochrome  P450  family  1  subfamily  A member  2  (CYP1A2),  respectively.  This  analysis  is
promising and, to the best of our knowledge, have not been sufficiently exploited so far.
(Insert Fig. 2)
The  central  and  right  panels  of  Fig,  2  show  genes,  ordered  according  to  their  differential
expressions, for the centers of the tumor clouds (geometric averages over tumor samples). Only the
tails  with  higher  over-  or  under-expressions  are  shown.  Notice  that  these  tails  contains  a  few
thousands of genes, the rest of the 60000 genes are not differentially expressed. The distributions
are not symmetrical. Whereas Kidney Papillary Cell Carcinoma (KIRP) is dominated by silenced
genes, LUSC has nearly equal proportions of under- and over-expressed genes, and in Liver Hepatic
Cell Carcinoma (LIHC)  the over-expressed genes are more numerous. Log-log plots stress that the
tails  exhibit  a  power-like  (Pareto,  [28,29])  behavior,  i.e.  the  number  of  genes  with  differential
expression greater than a given value is an inverse power of the expression. 
Statement  3.  Tumors  in  different  localizations  share  hundreds  or  even  thousands  of
differentially expressed genes. There are 6 genes common to 15 tumor localizations.
For each localization, we select the most significant 2500 genes with the largest contributions to the
vector  v1 along the PC1 direction defining the cancer state.  This number,  although arbitrary,  is
dictated by the previous results on the expression distribution function. Let us stress that these are
genes with significant differential expressions and great importance in the definition of the cancer
state.
Table II shows the number of shared genes for pairs of localizations. Notice that these numbers vary
in the interval between 314 and 1889. Large numbers of shared genes are characteristic of tumors in
the same organ but originating in different cells (lung, kidney). However, there are also tumors
sharing unexpectedly large numbers of genes. For example, tumors in the uterine corpus (UCEC)
and bladder (BLCA) share more than 1300 genes. 
(Insert Table II)
Let us stress that there are 49 genes common to a group of 11 tumors, PRAD-LUSC-LUAD-UCEC-
BLCA-ESCA-BRCA-HNSC-COAD-READ-STAD, and six genes  common to all  of  the  studied
localizations. They are MMP11 (+), C7 (-), ANGPTL1 (-), UBE2C (+), IQGAP3 (+) and ADH1B
(-). Their differential expressions are very similar in all of the studied tumors. The signs added in
parenthesis mean that the gene is over- or under-expressed in tumors. 
The six identified pan-cancer genes have been recently pointed out as playing a significant role in
many cancers  [30-35].  It  is  noteworthy that  these genes  are  straightforwardly related to cancer
hallmarks [36,37]: i.e. invasion, suppression of the immune response, angiogenesis, proliferation
and changes in metabolism. 
Shared genes among groups of tumors open the question about universal therapies for these groups. 
Below, we notice that pan cancer genes (the six ones common to all of the tumors) play a role in
both tissue differentiation and in the definition of the border between normal tissues and tumors. In
addition,  the  number  of  shared  genes  seems  to  be  related  to  the  proximity  of  tumors  in  the
expression space.
Statement 4. The tumor region is a kind of attractor. Tumors in advanced stages converge to
this region independently of patient age or genetic variability.
As may be seen in Fig. 1, regions corresponding to normal and tumor samples are well defined and
partially disjoint in the expression space. The sample variability comes from genetic differences,
patient  ages  and the  evolution  history of  each individual.  The fact  that,  in  spite  of  variability,
regions are well defined in expression space is in favor of the attractor paradigm of cancer [38-40]
in which the cancer region should be the region of confluence of all somatic evolution trajectories
out of the normal area. In a very reductionist view one may think, for example, about  normal
functioning and cancer as two stable solutions of a global gene regulatory network [41,42].
We may conduct a more precise test of the attractor hypothesis by studying the dependence of the
distribution functions on patient age. Let us consider, again, LUSC as an example. According to
age, in LUSC we may define 4 subgroups of samples: Normal Young (NY), Normal Old (NO),
Tumor Young (TY) and Tumor Old (TO). These subgroups are in some sense arbitrarily defined.
First,  the label “normal” refers to a pathologically normal sample from a patient with a tumor.
Second, in the example “young” labels samples where age is lower than 62 years. These conditions
are dictated by the availability of samples, as in any statistical analysis. 
Nevertheless,  the  results  are  very  interesting.  The  (over-)  expression  distribution  function  is
visualized  in  Fig.  3.  We  compute  (mean  geometric)  averages  over  the  NY,  NO,  TY and  TO
subgroups,  and  use  the  NY values  as  references  in  order  to  define  normalized  (differential)
expressions in the remaining subgroups: ēNO, ēTY, and ēTO. These vectors characterize the centers of
their  respective clouds of samples. Genes are sorted with regard to their  normalized expression
values. 
(Insert Fig. 3)
There  are  deviations  for  a  reduced  number  of  genes  in  the  NO group with  regard  to  the  NY
reference. This may be taken as a consequence of aging. In tumors, however, deviations are much
larger. There are around 1000 over-expressed genes with |ē| > 5. 
Most striking is the similarity between the distribution functions in the TY and TO subgroups. That
is, for tumors the distribution function in the final state is nearly independent of the age when tumor
initiates. This is an argument in favor of the attractor hypothesis. Similar results (not shown) are
obtained for the sub-expression tail. 
A slightly  different  test  comes  from considering  a  second  “time”  or  progression  variable:  the
clinically  determined  tumor  stage.  It  is  a  qualification  given  to  the  tumor  at  the  moment  of
diagnosis, but in some sense it quantifies also the  somatic evolution once the portion of the tissue
acquires the tumor condition. Fig. 4 shows the distribution of tumors by stages in Clear Cell Kidney
Carcinoma (KIRC). Normal tissues are represented by blue points, whereas tumors are drawn in
red. The four panels refer to the four stages: I, II, III and IV. Blue points are in the four panels, but
only red points with the corresponding stage are included in each panel.
(Insert Fig. 4) 
We use a contour plot and colors to visualize the total density of points in the state space. Two
regions of maximal density are apparent, corresponding to normal states and an optimal region for
tumors. Naively, one expects that tumors move along the transition region from the normal to the
tumor  region  as  the  stage  evolves  from I  to  IV.  In  the  actual  measurements,  we  don’t  track
individual tumors as function of stages, but get pictures of different tumors at different stages. Thus,
in the initial stages we should observe a fraction of red points captured in the transition region,
whereas in the final stages, most tumors should be concentrated in the optimal region. This is what
actually follows from the figure, again supporting the attractor paradigm. We may speculate that the
optimal region could be related to a region of maximal fitness for the tumor in the given tissue. 
The intuition induces us to relate the tumor stage to the coordinate along the tumor axis PC1. The
correspondence, however, is not exact. Although there seems to be a correlation between stage and
mean displacement towards the tumor region, many tumors in the initial stages are already at the
center of the cloud. This could be related to the fact that the observed distribution of samples is
probably related to the fitness distribution and the transition region should be a low-fitness zone. 
Statement 5. There is a landscape of cancer in gene expression space with an approximate
border separating normal tissues from tumors.
We consider the central goal of the paper: i.e. to draw a picture in which both normal tissues and
tumors  in  different  localizations  are  represented.  In  a  way,  this  is  a  picture  involving  tissue
differentiation  and  cancer.  It  is  not  surprising  that  pan  cancer  genes  will  play  a  role  in  both
processes.
We shall use the  enormal  and  etumor  (mean geometric) averages for each localization in order to
define cloud centers. The reference is to be computed by averaging over all  normal expression
vectors. Then, the ê magnitudes and the covariance matrix are obtained, and the latter diagonalized. 
The first aspect to be stressed is that the first two PCs accounts only for 37 % of the total data
variance.  The  relative  importance  of  these  two  variables  is  not  so  apparent  as  in  the  case  of
individual tissues. This is probably due to the big dispersion of the data for normal tissues, related
to tissue differentiation, sometimes even larger than separations between a normal tissue and the
respective tumor.
As a consequence of the dispersion of normal tissues, we do not have a “cancer axis” or direction,
as in individual tissues. In order to draw a frontier between normal and tumor regions, we shall
include higher PCs. The next component, PC3 accounts for 12 % of the data variance.
We show in Fig. 5 the (PC1, PC3) plane, which indeed suggests that there is a border. Actually, the
regions and the border are high dimensional, but the 2D figure captures the essential features. We
may baptize this figure as the “approximate normal vs cancer” or “tissue differentiation vs cancer”
plane. It is apparent from the figure, that the transition from a normal tissue to the corresponding
tumor implies crossing the border, and involves simultaneous displacements along the PC1 and PC3
axes. 
(Insert Fig. 5)
The unitary vectors along these axes allow the identification of genes with the highest weights. It is
very interesting that pan cancer genes are among the most important genes in these vectors. For
example, ADH1B and UBE2C are included in the set of 8 most important genes along PC1: PI3 (+),
ADH1B (-), MYBL2 (+), UBE2C (+), ALB (-), CEACAM5 (+), CST1 (+) and MMP1 (+).  
A more detailed analysis of the border between normal tissues and tumors is required. In the present
paper, we limit ourselves to draw the global picture, and leave this analysis for a future work.
We would  like  to  notice  that distances  between  pairs  of  tumors  in  gene  expression  space  are
inversely correlated with the number of shared genes which define the cancer state. This fact is
partially  reflected  in  Fig.  5  because  the  distances  in  this  figure  are  not  true  distances,  but
projections. 
DISCUSSION
We performed PC analysis of gene expression data for 15 tumors. Our results are approximate and
semi-quantitative, in the sense that they could be modified if a larger data set become available, but
at the same time they are simple, general and unbiased, in the sense that no modeling or elaborated
mathematical treatments are used. We try to keep interpretation of results as close as possible to the
facts.
Both  somatic  evolution  in  a  normal  tissue,  and  the  transition  to  a  tumor  state  involves  the
modification  of  thousands  of  genes.  However,  these  genes  do  not  act  independently,  but  in  a
concerted way. The number of relevant PC coordinates for a tissue (or a portion of it), which seems
to be around 10, may be interpreted as the effective number of degrees of freedom of the biological
system. 
These variables, although of statistical origin, can be used to describe the state and evolution of the
tissue, in particular one of the variables measures the progression from normal to cancer state (the
projection on PC1, the cancer axis) and allows the definition of a profile of genes involved in this
progression. 
The data seem to support the theory of cancer as an attractor, that is once a portion of the tissue
escapes from the normal region it is driven to the cancer basin of attraction. 
The existence of a ranking of genes in the definition of the cancer state, allows us to speculate about
the possibility to stop progression if the tumor is diagnosed in the initial stage. Indeed, what would
happen if we target a few of the most significant genes in the cancer profile? Could this kind of
intervention induce a rearrangement of the whole profile preventing the tumor to evolve to more
advanced stages? This is an interesting question with possible implications for therapy. 
Questions are also raised in relation to the second important conclusion of our paper, related to the
overall  landscape in gene expression space: not only individual tissues are separated from their
respective tumors, but the set of normal tissues are separated from the set of tumors. In a very rough
analysis, we noticed that pan cancer genes (i.e, common to all 15 tumors) are involved both in tissue
differentiation and in the definition of the border. One possible, very interesting question is the
following: what could this relationship tell us about tumors in early childhood, which initiate in the
developmental period? On the other hand, one can imagine therapies that make use of the complex
landscape represented in Fig. 5. For example, could we target the main genes connecting a tumor
and a different nearby (in GE space) normal tissue? Would this intervention reduce the tumor fitness
in the original tissue leading to a regression?  
In the paper, we focused on qualitative aspects. However, there is the possibility to quantify and to
model some aspects of cancer. For example, notice that from figures like Fig. 1 we can estimate the
dimensions of the normal and cancer regions in gene expression space and the distance between
their centers. From this data, and the statement that progression is described by a single variable one
may possibly devise a one dimensional model for tumorigenesis in a given tissue [43].
Work along some of these directions is in progress [44,45].
METHODS
The results of the paper are based on the analysis of TCGA data for gene expression in FPKM
format.  The  number  of  genes  is  60483.  This  is  the  dimension  of  matrices  in  the  Principal
Component analysis.
We selected the 15 cancer types shown in Table I on the basis of two conditions: i) The number of
normal samples is greater than 10, and ii) The number of tumor samples is greater than 160.
We show in Fig. S1 expressions from a typical data file (PRAD case). Notice that there are around
28000  not  transcribed  genes  (expression  exactly  zero),  and  only  around  25000  genes  with
expression above 0.1.
Usually, in order to compute the average expression of a gene the median or the geometric mean are
used. We prefer geometric averages, but then the data should be slightly distorted to avoid zeroes.
To this end, we added a constant 0.1 to the data. By applying this regularization procedure, genes
identified as relevant could be under question if the differential expression is relatively low and
their expression in normal tissues is near zero. As we are mainly interested in the strongly over- or
under-expressed genes, they are out of the question.
For each cancer localization, we take the mean geometric average over normal samples in order to
define the reference expression for each gene, eref. Then the normalized or differential expression is
defined as:  ē = e/eref. The fold variation is defined in terms of the base 2 logarithm ê = Log2 (ē).
Besides  reducing  the  variance,  the  logarithm  allows  treating  over-  and  sub-expression  in  a
symmetrical way. 
Deviations and variances are measured with respect to  ê = 0. That is, with respect to the average
over normal samples. This election is quite natural, because normal samples are the majority in a
population, individuals with cancer are rare. 
With these assumptions, the covariance matrix is written:
σ2ij = Σ  êi(s) êj(s) / (Nsamples-1)
where the sum runs over the samples, s, and Nsamples is the total number of samples. êi(s) is the fold 
variation of gene i in sample s.
As  mentioned,  the  dimension  of  matrix  σ2 is  60483.  By diagonalizing  it,  we  get  the  axes  of
maximal variance: the Principal Components (PCs). They are sorted in descending order of their
contribution to the variance. 
In LUSC, for example, PC1 accounts for 67% of the variance. This large number is partly due to
our choice of the reference,  ê = 0, and the fact that most of the samples are tumors. The reward is
that PC1 may be defined as the cancer axis.  The projection over PC1 defines whether a sample is
classified as normal or tumor. 
The next PCs account for a smaller fraction of the variance. PC2 is responsible of 4%, PC3 of 3%,
etc.  Around 10 PCs are enough for an approximate description of the region of the gene expression
space occupied by the set of samples.
Thus, we need only a small number of the eigenvalues and eigenvectors of σ2. To this end, we use
a Lanczos routine in Python language, and run it in a node with 2 processors, 12 cores and  64 GB
of RAM memory. As a result, we get the first 100 eigenvalues and their corresponding eigenvectors.
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Cancer type 
(TCGA 
notation)
Normal 
samples 
Tumor samples
KIRP 32 289
KIRC 72 539
PRAD 52 499
LUSC 49 502
LUAD 59 535
UCEC 23 552
BLCA 19 414
COAD 41 473
ESCA 11 160
LIHC 50 374
STAD 32 375
BRCA 112 1096
HNSC 44 502
THCA 58 510
READ 10 167
Table I. The set of data analyzed in the paper. 
KIRC PRAD LUSC LUAD UCEC BLCA COAD READ ESCA STAD BRCA HNSC LIHC THCA
KIRP 1213 534 642 625 696 643 543 545 532 464 646 523 459 600
KIRC 488 507 551 493 472 537 516 558 455 468 576 462 475
PRAD 561 608 774 789 621 712 573 597 730 581 485 481
LUSC 1454 857 932 634 591 1011 699 871 805 539 531
LUAD 863 883 801 731 778 803 908 725 628 528
UCEC 1313 710 831 702 784 1118 691 502 583
BLCA 813 935 817 965 1101 785 615 562
COAD 1889 682 994 722 622 512 517
READ 587 951 761 567 450 518
ESCA 977 697 1069 639 502
STAD 700 859 630 433
BRCA 707 555 589
HNSC 612 485
LIHC 314
Table II. Number of common differentially-expressed genes in pairs of localizations.
Fig.  1.  Principal  Component Analysis  of  the TCGA gene expression data for three  of  the
studied tumors. The left panel contains the (PC1, PC2) plane, whereas the right panel shows the
variance captured by the first n PCs.
Fig. 2. Left panel. The 30 genes with highest weights in the definition of the cancer state. The same
tumors as in Fig. 1 are used as examples. The numbering of genes is the one used in the TCGA data.
To  simplify  drawing,  the  contributions  of  the  remaining  genes  are  set  to  zero.  Positive  signs
correspond to over-expressed, and negative to sub-expressed genes.   Central and right panels.
Integrated gene expression distribution functions, over- and under-expression tails are shown.
Fig. 3 Integrated gene (over) expression distribution functions in LUSC.  According to age,
samples are grouped into four sets: Normal Young (NY), Normal Old (NO), Tumor Young (TY) and
Tumor Old (TO). The average over the NY set is used to define reference values to normalize the
expressions.  Each set of points represents the average over the respective group. 
Fig. 4. Stages in the evolution of tumors in Clear Cell Kidney Cancer (KIRC). Blue points are
normal tissues (included in the four panels), whereas red points are tumors in a given stage of
evolution.  Contours represent the total density of points. Stage I seems to be “transitional”, there
are many points traveling along the intermediate region. On the other hand, stages II, III and IV are
“final”, in the sense that most of the tumors are concentrated in the high density region. This picture
reinforces the attractor paradigm of cancer. We may speculate that the attractor is the region of the
state space with maximal fitness for the tumor in the given tissue.
Fig.  5.  The gene expression landscape in the  (PC1,  PC3) plane.  Each point  in  the  diagram
represents the average of samples in a given localization. For simplicity, normal tissues are labeled
with the corresponding tumor indexes.  The approximate border  between the normal  and tumor
regions is drawn.
Fig. S1 (Supplementary Fig. 1). Range of values in a typical data file. Roughly half of the 60000
genes are not transcribed.
